The results revealed that nonclassical MYB fusions, including MYB–TGFBR3 and MYB–RAD51B fusions, accounted for approximately 2.2% (29 out of 1294) of ACC patients (Figure 2A). Here, MYB is linked to adrenal cortex carcinoma.